Alexion Pharmaceuticals, Inc.’s Post

Starting a clinical trials revolution with Protas: watch the exclusive talk with Sir Martin Landray, to find out how Protas are using ground-breaking tech from Salesforce and data-driven advancements to reduce the cost of large, randomised clinical trials by ten-fold. Shot at Fierce JPM, watch the full video to discover how, together, we're breaking barriers for better treatments in common diseases. Link to full video here: https://bit.ly/3OyCM2Y #ClinicalTrials#HealthTech

Starting a clinical trials revolution with Protas: watch the exclusive talk with Sir Martin Landray, to find out how Protas are using ground-breaking tech from Salesforce and data-driven advancements to reduce the cost of large, randomised clinical trials by ten-fold. Shot at Fierce JPM, watch the full video to discover how, together, we're breaking barriers for better treatments in common diseases. Link to full video here: https://bit.ly/3OyCM2Y #ClinicalTrials#HealthTech

What happens when innovative tech meets the challenge of rare diseases? Focusing on rare conditions requires a tailored, patient-centred approach as medical and technological advancements continue to evolve. While these conditions affect fewer people individually, they collectively impact a significant number of individuals, making it crucial to address their unique challenges. McKinsey shares a four-part framework for achieving a patient-centric approach in rare-conditions space: #PatientCentricity #RareDiseases #PatientEngagement

Meet me at the BioTechX conference in Basel to learn how we handle compliance and security as well as our technical and AI/ML capabilities, talk to Joseph Hayes about our scientific and clinical accomplishments and talk to Bettina Duehrkoop about how juli can help you help and engage your customers and end-users sustainably. #BioTechX #digitalhealth #healthcaretransformation #AIforHealthcare

Are you researching Long COVID? 🔍 Submit an abstract for the inaugural regional edition of our #LongCovid conference series – Demystifying Long Covid North American Conference 2024. Be part of the evolving field of Long Covid diagnostics & treatment, the abstract portal is open until 5 April at 23:59 EDT. View the categories and submit here 👉amededu.co/4ct2H6G #DemystifyingLongCovid #LongCovid #PostCOVID

Next Thursday, February 29th, is Rare Disease Day - the rarest day of all! I am so honored to speak at the Clinical Research Data Sharing Alliance #CRDSA about the future of data for #rarediseases from #artificialintelligence and #machinelearning to #innovative #trialdesigns, the use of #realworlddata and #realworldevidence, and so much more!

The new science of inflammation: sometimes hero, sometimes enemy - Part II My "Longevity Tips" newsletter gives one actionable, easy to do tip each month, based upon what I've learned through travels to longest living populations plus the best of science. The April issue will publish soon. You can get it here: https://lnkd.in/g8Ch85xs #longevity #diseasesofinflammation #inflammation Please share with one other person if you found this helpful.

As #IntelliaTurns10, we pause to reflect on why this work matters. It's not just about the science, but the potential impact it has on people living with serious diseases. Our #GenomeJourney has only just begun, and we can't wait to see where it takes us. Tune in for part 4 of our 10th-anniversary series! www.intelliatx.com

We are pleased to support the 8th Update on Fabry Disease meeting where experts from the scientific and medical communities will join together to share the latest research and discuss important advances related to the management of #Fabry disease. Learn more: https://lnkd.in/eUtSTxyu   #RareDiseases #ChiesiGlobalRareDiseases

Traditional clinical trials provide crucial data, but what about patients facing real-world challenges? KMK integrates Burden of Illness (BOI) studies with Real-World Evidence (RWE) to uncover the full spectrum of a disease's impact. Our patient-centric approach ensures faster access to effective treatments based on robust real-world data. Ready to make a real difference? 📩 DM us today!